Faeth Therapeutics
FTH
25 hedge funds and large institutions have $3.92M invested in Faeth Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 8 closing their positions.
0.83% less ownership
Funds ownership: 9.39% → 8.56% (-0.83%)
12% less capital invested
Capital invested by funds: $4.47M → $3.92M (-$550K)
17% less funds holding
Funds holding: 30 → 25 (-5)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$1.09M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$67.8K |
| 3 |
VF
Virtu Financial
New York
|
+$38.3K |
| 4 |
DCM
Deuterium Capital Management
Clearwater,
Florida
|
+$17.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$17.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.06M |
| 2 |
BlackRock
New York
|
-$202K |
| 3 |
E
Ergoteles
New York
|
-$81.8K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$78K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$73.5K |
FTH Hedge Fund Activity: Q4 2022 in Review
25 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q4 2022, worth a combined $3.92M — down 12% from $4.47M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of FTH and 4 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was Newtyn Management, adding an estimated $1.09M. The largest seller was RA Capital Management, exiting entirely with an estimated $1.06M sold.
- 25 institutional investors held Faeth Therapeutics (FTH) as of Q4 2022, down from 30 in Q3 2022.
- Funds reported $3.92M of Faeth Therapeutics stock for Q4 2022, down 12% quarter-over-quarter.
- 4 funds opened new Faeth Therapeutics positions in Q4 2022 and 8 closed out, a net change of -4 holders.
- The largest Faeth Therapeutics buyer in Q4 2022 was Newtyn Management, an estimated $1.09M added.
- The largest Faeth Therapeutics seller in Q4 2022 was RA Capital Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2022.